Get expert US stock recommendations backed by technical analysis, market trends, and institutional activity to maximize returns while minimizing downside risk. Our team of experienced analysts monitors market movements daily to identify high-potential opportunities for your portfolio. Access comprehensive research, real-time alerts, and actionable strategies designed to optimize your investment performance. Start making smarter investment decisions today with our free platform offering professional-grade insights for investors at all levels.
This analysis covers the April 24, 2026 announcement that Bristol Myers Squibb (NYSE: BMY) and co-marketing partner Pfizer (NYSE: PFE) will list their top-selling anticoagulant Eliquis on the Mark Cuban Cost Plus Drug Company (MCCPDC) platform starting the following week, priced at $345 for a 30-day
Bristol Myers Squibb (BMY) - Partners With Pfizer to List Blockbuster Anticoagulant Eliquis on Mark Cuban Cost Plus Platform at $345 Monthly - Crowd Risk Alerts
BMY - Stock Analysis
4924 Comments
1705 Likes
1
Kaionna
Insight Reader
2 hours ago
So late to see this… oof. 😅
👍 281
Reply
2
Cheyene
Loyal User
5 hours ago
So much heart put into this. ❤️
👍 152
Reply
3
Volvi
Daily Reader
1 day ago
Short-term consolidation may lead to a fresh breakout.
👍 271
Reply
4
Raiyne
Active Reader
1 day ago
Indices continue to hold above critical support levels, signaling resilience in the broader market. While profit-taking may occur in select sectors, technical indicators suggest that the overall trend remains upward. Traders are closely monitoring volume and breadth to confirm the continuation of positive momentum.
👍 297
Reply
5
Quiniya
Regular Reader
2 days ago
Absolute mood right there. 😎
👍 197
Reply
© 2026 Market Analysis. All data is for informational purposes only.